EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Mol Cancer Ther 2016 07 11;15(7):1627-36. Epub 2016 May 11.

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Although treatment of BRAF V600E-mutant non-small cell lung cancer (NSCLC(V600E)) with GSK2118436 has shown an encouraging efficacy, most patients develop resistance. To investigate the mechanisms of acquired resistance to GSK2118436 in NSCLC(V600E), we established GSK2118436-resistant (GSR) cells by exposing MV522 NSCLC(V600E) to increasing GSK2118436 concentrations. GSR cells displayed activated EGFR-RAS-CRAF signaling with upregulated EGFR ligands and sustained activation of ERK1/2, but not MEK1/2, in the presence of GSK2118436. Treatment of GSR cells with GSK2118436 enhanced EGFR-mediated RAS activity, leading to the formation of BRAF-CRAF dimers and transactivation of CRAF. Interestingly, sustained activation of ERK1/2 was partly dependent on receptor-interacting protein kinase-2 (RIP2) activity, but not on MEK1/2 activity. Combined BRAF and EGFR inhibition blocked reactivation of ERK signaling and improved efficacy in vitro and in vivo Our findings support the evaluation of combined BRAF and EGFR inhibition in NSCLC(V600E) with acquired resistance to BRAF inhibitors. Mol Cancer Ther; 15(7); 1627-36. ©2016 AACR.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0375DOI Listing
July 2016
65 Reads

Publication Analysis

Top Keywords

gsr cells
12
acquired resistance
12
resistance gsk2118436
8
braf v600e-mutant
8
combined braf
8
egfr inhibition
8
braf egfr
8
sustained activation
8
activation erk1/2
8
gsk2118436
6
braf
5
leading formation
4
formation braf-craf
4
braf-craf dimers
4
activity leading
4
egfr-mediated ras
4
ras activity
4
dimers transactivation
4
craf interestingly
4
dependent receptor-interacting
4

Similar Publications